Kyverna Therapeutics Stock Quote KYTX - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

9.00

Bid

9.00

Ask

9.08

Volume

37,267

8.91 Day's Range 9.28

6.75 52 Week Range 35.01

Market Cap

388.037M

Previous Close

8.92

Open

9.00

Last Trade

9.04

Last Trade Time

10:54:41

Financial Volume

$ 338,452

VWAP

9.0818

Average Volume (3m)

596,780

Shares Outstanding

43,115,244

Dividend Yield

PE Ratio

-6.48

Earnings Per Share (EPS)

-1.4

Revenue

Net Profit

-60.37M

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin... Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

kyvernatx.com

Headquarters

Dover, Delaware, USA

Founded

1970

Kyverna Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KYTX. The last closing price for Kyverna Therapeutics was $8.92. Over the last year, Kyverna Therapeutics shares have traded in a share price range of $ 6.75 to $ 35.01.

Kyverna Therapeutics currently has 43,115,244 shares outstanding. The market capitalization of Kyverna Therapeutics is $384.59 million. Kyverna Therapeutics has a price to earnings ratio (PE ratio) of -6.48.

Form 8-K - Current report

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome PR Newswire EMERYVILLE, Calif., July 15, 2024 The application...

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial PR Newswire EMERYVILLE, Calif., June 20...

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) PR Newswire EMERYVILLE...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology PR Newswire EMERYVILLE, Calif., June 10, 2024...

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 PR Newswire EMERYVILLE, Calif., June 7, 2024 Data to include insights from 12 indications from more than...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.8	-16.6666666667	10.8	11.24	8.81	381941	9.7925034	CS
4	1.92	27.1186440678	7.08	11.4	6.895	493891	9.03377706	CS
12	-7.56	-45.652173913	16.56	17.55	6.75	596780	10.69351991	CS
26	-25.25	-73.7226277372	34.25	35.01	6.75	519401	16.7662072	CS
52	-25.25	-73.7226277372	34.25	35.01	6.75	519401	16.7662072	CS
156	-25.25	-73.7226277372	34.25	35.01	6.75	519401	16.7662072	CS
260	-25.25	-73.7226277372	34.25	35.01	6.75	519401	16.7662072	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
POAIPredictive Oncology Inc	$ 2.335 (118.22%)	126.71M
PBMPsyence Biomedical Ltd	$ 0.6688 (70.87%)	61.43M
XCURExicure Inc	$ 0.68 (70.47%)	12.15M
SLRXSalarius Pharmaceuticals Inc	$ 2.9197 (36.43%)	14.87M
GSHDGoosehead Insurance Inc	$ 84.75 (29.00%)	402.12k
TWOU2U Inc	$ 1.43 (-65.29%)	2.43M
KDLYKindly MD Inc	$ 2.02 (-37.27%)	435.24k
EZFLEzFill Holdings Inc	$ 3.97 (-36.22%)	89.54k
ATPCAgape ATP Corporation	$ 0.1089 (-31.51%)	3M
CMMBChemomab Therapeutics Ltd	$ 0.995 (-29.93%)	1.98M
NVDANVIDIA Corporation	$ 113.21 (-0.91%)	189.98M
POAIPredictive Oncology Inc	$ 2.335 (118.22%)	126.71M
SLNASelina Hospitality PLC	$ 0.0408 (-10.72%)	126.55M
SQQQProShares UltraPro Short QQQ	$ 9.165 (1.16%)	99.23M
PBMPsyence Biomedical Ltd	$ 0.6688 (70.87%)	61.43M